Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Hematologic Neoplasms 4Urologic Neoplasms 1Urologic Diseases 1Urogenital Neoplasms 1Myelodysplastic Syndromes 1Monoclonal Gammopathy of Undetermined Significance 1Lung Neoplasms 1Hypogonadism 1Hematopoietic and Lymphatic System Neoplasm 1Heart Failure 1Colitis 1Central Nervous System Neoplasms 1Cardiomyopathies 1Carcinoma, Non-Small-Cell Lung 1Anemia, Aplastic 1

Interventions

Azacitidine 56Cyclophosphamide 44fludarabine phosphate 42fludarabine 37Decitabine 27venetoclax 26Cytarabine 25Tacrolimus 20Specimen Handling 18Filgrastim 18Busulfan 18Melphalan 17Whole-Body Irradiation 16Mycophenolic Acid 16Antilymphocyte Serum 14Granulocyte Colony-Stimulating Factor 12Clofarabine 12Biopsy 12Peripheral Blood Stem Cell Transplantation 11Injections 11Etoposide 11Methotrexate 10thymoglobulin 9Thiotepa 9Stem Cell Transplantation 9Lenalidomide 9decitabine and cedazuridine drug combination 8aldesleukin 8Sirolimus 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myelodysplastic Syndromes × Practice Guidelines as Topic × Clear all
NCT04439006 2023-12-26

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
10 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Aplastic, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndromes, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡